By Fineline Cube 
Mabwell Bioscience (SHA: 688062) disclosed a strategic, deep‑level collaboration with Ping An Healthcare and Technology Company Limited (HKG: 1833). The alliance will develop end‑to‑end online‑offline solutions spanning product distribution, medical‑service innovation, and a new digital ecosystem for the full‑course management of bone health and autoimmune diseases.
Deal Overview
| Aspect | Detail |
|---|---|
| Partners | Mabwell (688062.SH) & Ping An Health (1833.HK) |
| Collaboration Type | Deep‑level business partnership |
| Announcement Date | 11 Nov 2025 |
| Core Objective | Integrated online‑offline platform for bone‑health & autoimmune disease management |
| Target Audience | Patients with age‑related tumors, autoimmune conditions, and bone‑health issues; elderly care market |
| Key Levers | Patient‑centric service model, AI‑driven tools, managed‑care expertise, extensive user base |
Strategic Rationale
- Mabwell brings a robust pipeline of high‑potential therapeutics for age‑related cancers and autoimmune disorders.
- Ping An Health contributes a massive digital user ecosystem, a proven managed‑care framework, and deep expertise in medical, health, and elder‑care services.
- The partnership aligns with both firms’ “medicine + healthcare + insurance/services” vision, aiming to accelerate high‑quality medical resource delivery and reduce patient out‑of‑pocket costs.
Planned Digital Ecosystem
- Online Full‑Course Management Platform – AI‑powered portal covering disease education, risk screening, diagnosis, treatment, follow‑up, and rehabilitation guidance.
- Integrated Payment & Reimbursement Model – Real‑time pharma‑marketing analytics and innovative payment solutions to improve drug adherence and rational use.
- One‑Stop Service Suite – Seamless connection of medical services, health monitoring, and insurance benefits for bone‑health and autoimmune patients.
Market Impact & Outlook
- Revenue Potential: Mabwell projects ¥1.5 billion (≈ US$210 million) in incremental sales by 2028 from the joint platform, assuming capture of 4 % of the estimated 30 million Chinese patients needing chronic bone‑health or autoimmune care.
- Competitive Edge: The combined AI‑driven, patient‑centric approach differentiates the offering from traditional pharma‑only models and from stand‑alone tele‑health services.
- Regulatory & Reimbursement: Both parties will work with Chinese health authorities to embed the platform within the national “Internet + Healthcare” policy framework, facilitating faster drug approval pathways and insurance coverage.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the collaboration’s commercial expectations, regulatory environment, and market adoption. Actual results may differ due to risks including technology integration challenges, regulatory approvals, and competitive dynamics.-Fineline Info & Tech